Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olanzapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.98 |
| ▸ | HTR2C known ✓ | P28335 | 5/20 | 0.98 |
| ▸ | DRD4 known ✓ | P21917 | 4/20 | 0.98 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.98 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.98 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.98 |
| ▸ | DRD1 | P21728 | 5/20 | 0.98 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.98 |
| ▸ | HRH1 | P35367 | 5/20 | 0.98 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.98 |
| ▸ | HTR2B | P41595 | 5/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olanzapine SCHEMBL5091769 | 1.00 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1634614 | 1.00 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1830363 | 0.99 | CHRM1 (0.95) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL16114506 | 0.99 | CHRM1 (0.95) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL28763 | 0.99 | CHRM1 (1.00) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL4775632 | 0.99 | CHRM1 (1.00) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL29358280 | 0.99 | CHRM1 (1.00) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1376031 | 0.98 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL6461808 | 0.98 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL2222724 | 0.98 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323459-B2 | Crystal forms, methods for their preparation and method for preparation of olanzapine | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-01-29 | — | — | US | claimed |
| EP-1575962-A1 | NOVEL CRYSTAL FORMS OF OLANZAPINE, METHODS FOR THEIR PREPARATION AND METHOD FOR THE PREPARATION OF KNOWN OLANZAPINE CRYSTAL FORMS | Teva Pharmaceutical Industries Limited (IL) | 2005-09-21 | — | — | EP | claimed |
| US-20040198721-A1 | Novel crystal forms, methods for their preparation and method for preparation of olanzapine | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-10-07 | — | — | US | claimed |
| WO-2004058773-A9 | NOVEL CRYSTAL FORMS OF OLANZAPINE, METHODS FOR THEIR PREPARATION AND METHOD FOR THE PREPARATION OF KNOWN OLANZAPINE CRYSTAL FORMS | TEVA PHARMA (IL) | 2004-08-19 | — | — | WO | claimed |
| WO-2004058773-A1 | NOVEL CRYSTAL FORMS OF OLANZAPINE, METHODS FOR THEIR PREPARATION AND METHOD FOR THE PREPARATION OF KNOWN OLANZAPINE CRYSTAL FORMS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-07-15 | — | — | WO | claimed |
| EP-1313742-A1 | PROCESS FOR PREPARATION OF HYDRATES OF OLANZAPINE AND THEIR CONVERSION INTO CRYSTALLINE FORMS OF OLANZAPINE | Dr. Reddy's Laboratories Ltd. (IN) | 2003-05-28 | — | — | EP | claimed |
| WO-2002018390-A1 | PROCESS FOR PREPARATION OF HYDRATES OF OLANZAPINE AND THEIR CONVERSION INTO CRYSTALLINE FORMS OF OLANZAPINE | DR. REDDY'S LABORATORIES LTD. (IN) | 2002-03-07 | — | — | WO | claimed |
| US-10624875-B2 | Methods and compositions for treating schizophrenia | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-04-21 | — | — | US | disclosed |
| EP-3610890-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | The Johns Hopkins University (US) | 2020-02-19 | — | — | EP | disclosed |
| US-10154988-B2 | Methods and compositions for treating schizophrenia | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-12-18 | — | — | US | disclosed |
| US-20180125818-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | THE JOHNS HOPKINS UNIVERSITY | 2018-05-10 | — | — | US | disclosed |
| US-20150313876-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | THE JOHNS HOPKINS UNIVERSITY | 2015-11-05 | — | — | US | disclosed |
| EP-2919788-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | The Johns Hopkins University (US) | 2015-09-23 | — | — | EP | disclosed |
| EP-1551414-A2 | CRYSTAL FORMS OF OLANZAPINE AND PROCESSES FOR THEIR PREPARATION | KRKA, D.D., Novo Mesto (SI) | 2005-07-13 | — | — | EP | disclosed |
| US-20040198721-A1 | Novel crystal forms, methods for their preparation and method for preparation of olanzapine | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-10-07 | — | — | US | disclosed |
| WO-2004058773-A9 | NOVEL CRYSTAL FORMS OF OLANZAPINE, METHODS FOR THEIR PREPARATION AND METHOD FOR THE PREPARATION OF KNOWN OLANZAPINE CRYSTAL FORMS | TEVA PHARMA (IL) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004058773-A1 | NOVEL CRYSTAL FORMS OF OLANZAPINE, METHODS FOR THEIR PREPARATION AND METHOD FOR THE PREPARATION OF KNOWN OLANZAPINE CRYSTAL FORMS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004056833-A1 | A PROCESS FOR THE PREPARATION OF A PHARMACEUTICALLY PURE POLYMORPHIC FORM I OF OLANZAPINE | ADAMED SP. Z O.O. (PL) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004006933-A2 | CRYSTAL FORMS OF OLANZAPINE AND PROCESSES FOR THEIR PREPARATION | KRKA, D.D., NOVO MESTO (SI) | 2004-01-22 | — | — | WO | disclosed |
| CN-1466588-A | Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine | 雷迪实验室有限公司 | 2004-01-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313876-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | RAB2A, SYNGR2, GRIN2A | DRD2 1076/4885HTR2A 5/4885HTR2C 47/4885 |
| US-10154988-B2 | Methods and compositions for treating schizophrenia | RAB2A, SYNGR2, GRIN2A | DRD2 1076/4885HTR2A 5/4885HTR2C 47/4885 |
| US-10624875-B2 | Methods and compositions for treating schizophrenia | RAB2A, SYNGR2, GRIN2A | DRD2 901/4885HTR2A 5/4885HTR2C 27/4885 |
| US-20180125818-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | RAB2A, SYNGR2, GRIN2A | DRD2 901/4885HTR2A 5/4885HTR2C 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.